ASD-43

ASD-43 is a novel selenium-aspirin hybrid molecule developed as a potential cancer therapeutic. It was designed by incorporating a selenide moiety into the aspirin scaffold to enhance the anti-cancer properties of the non-steroidal anti-inflammatory drug (NSAID). In preclinical studies, ASD-43 demonstrated significant cytotoxicity against various cancer cell lines, including colon (HCT116) and pancreatic (MiaPaCa-2) cancer cells, with IC50 values of 2.5 μM and 5.0 μM respectively after 48 hours of treatment. The compound induces apoptosis, evidenced by caspase-mediated PARP cleavage. Unlike its parent compound aspirin, ASD-43 shows potent dose-dependent reduction in cell viability at concentrations where aspirin is ineffective. It was developed by researchers at the Penn State University College of Medicine.

Other names

Se-aspirin hybridselenium-aspirin hybrid